São Paulo deny wrongdoing over Mounjaro use, highlight tailored treatments | OneFootball

São Paulo officially responded after the publication of a report by UOL that pointed to the use of the slimming pen Mounjaro in two players from the main squad as one of the factors of internal tension in the medical department.

According to the report, the prescription of the medication was allegedly made by nutritionist Eduardo Rauen, a specialist in sports medicine who handles specific cases at SuperCT and maintains a private practice in the Cidade Jardim area, in São Paulo. However, the recommendation was not communicated to some of the club's doctors, which fueled the internal crisis, marked by the space dispute between TecFut, a laboratory led by Rauen and hired to work at the Barra Funda CT, and older members of the department.

However, the tricolor management denied that there was any irregular or widespread use of the medication and called the association between Mounjaro and the high number of injuries in the squad a “false controversy.” In a statement sent to the press, the club stated that only two athletes received the prescription, on a specific basis and after individualized clinical evaluations.

“Individualized medical treatments were carried out, indicated specifically after careful clinical evaluations in only two athletes of the professional team, and not in a generalized, continuous, and indiscriminate manner. It is, at the very least, dishonest to point to the medication as the reason for the high number of injuries in the season,” highlighted the statement.

São Paulo also emphasized that Mounjaro, a medication based on tirzepatide, originally developed for type 2 diabetes and obesity, is approved by Anvisa and manufactured by the pharmaceutical company Eli Lilly, one of the largest in the world. The club stated that there is no irregularity in its use, as long as it is prescribed and monitored by a qualified professional, as was the case in the mentioned instances.

The club reinforced that it “values the health of its athletes in all categories” and assured that all medical practices, whether by consultants, providers, or collaborators, follow the current ethical and legal standards.

SEE MORE: Oscar should meet with São Paulo to discuss retirement

Restructuring in the Medical Department

This episode adds to one of the most turbulent years for the tricolor medical department. Throughout the season, the club recorded 70 injuries, 36 of which were muscular, a number higher than the total matches played in 2025.

Amid internal wear and external pressure, the management has already begun a deep restructuring of the sector. Last week, 11 professionals from the medical department were dismissed.

Read São Paulo's full statement:

“Regarding the false controversy about the use of the Mounjaro medication, São Paulo clarifies that:

– Individualized medical treatments were carried out, indicated specifically after careful clinical evaluations in only two athletes of the professional team, and not in a generalized, continuous, and indiscriminate manner. It is, at the very least, dishonest to point to the medication as the reason for the high number of injuries in the season.

– Mounjaro is a regularized and authorized medication by Anvisa, manufactured by Eli Lilly, one of the largest and most respected laboratories in the world. There is no irregularity in the use of the product, as long as it is of original manufacturing origin and, as in the case, with indication, monitoring, and medical prescription.

– The club values the health of its athletes in all categories and, therefore, always seeks professional excellence in all health departments.

– Any conduct in the health area practiced by professionals at the club, whether providers, consultants, or collaborators, is carried out within all the norms and regulations required by professional ethics and current legislation.”

This article was translated into English by Artificial Intelligence. You can read the original version in 🇧🇷 here.